Advanced Cell Technology Advances to Green Zone (ACTC)

Advanced Cell Technology (OTC: ACTC) closed in the green today at $0.084, with 1.3% minor gain in share price, comparing with yesterday’s larger rally of over 20%. Volume of the stock also spiked to a total of 18.3 million shares, bypassing its average of 5.4 million.

With its recent rally, Advanced Cell Technology stock is in the green zone, with a total gain of 2.4% in share price since the start of 2012. Share price of the stock surged in January and peaked at $0.179 on January 23, 2012, which has been Advanced Cell Technology’s highest closing price year-to-date. The stock fell sharply the next week and had been steadily declining until recently.

Advanced Cell Technology has been promoted by a number of newsletters. Stockpromoters.com listed 198 results regarding the stock promotion of Advanced Cell Technology, while none of the recent promotions were listed as being compensated. According to @pennystock24 on Twitter, Stock Blaster promoted Advanced Cell Technology today.

Here are some recent headlines for Advanced Cell Technology:

  • July 12, 2012, Advanced Cell Technology announced first Stargardt’s Macular Dytrophy patient treated with higher dosage of embryonic stem cell-derived retinal pigment epithelial cells.
  • July 9, 2012: Advanced Cell Technology announced that the Data and Safety Monitoring Board has authorized the company to move forward with enrollment and treatment of additional patients in its clinical trial for dry age-related macular degeneration.
  • July 2, 2012: Advanced Cell Technology announced treatment of the second patient in its Phase 1/2 clinical trial for Stargardt’s Macular Dytrophy using retinal pigment epithelial cells derived from human embryonic stem cells.
  • June 14, 2012: Advanced Cell Technology announced that the company was presenting at two upcoming conferences: The 2012 Bio International Convention and Clinical Outlooks for Regenerative Medicine meeting, both in Boston.

Advanced Cell Technology was incorporated in 2000. It is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine.

The company has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research.

The company’s emerging field of treatment, called regenerative medicine or cell therapy, refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury. It focuses on the development of effective methods to generate replacement cells from both human embryonic and adult stem cells.

The company has also secured FDA (Food and Drug Administration) clearance to proceed to a Phase II Clinical Trial for its Myoblast program for the treatment of heart failure, and the trial is being developed.

In September 2011, it received approval from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to conduct an SMD clinical trial in the United Kingdom.

The company owned licenses to over 35 issued patents and over 170 patent applications in the field of regenerative medicine and stem cell therapy.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Fiona Gibson

Fiona is a finance graduate and an expert in analyzing market trends.

Recent Stories

SignUp Now For Our Featured Newsletter